Please check your internet connection and try again.
# Sompraz HP (Sompraz)
## Overview
Sompraz HP is a combination product containing lansoprazole, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori* infection. Lansoprazole is a proton pump inhibitor (PPI), while amoxicillin and clarithromycin are antibiotics.
## Primary Indications
* Eradication of *Helicobacter pylori* infection in patients with peptic ulcer disease or a history of peptic ulcer disease.
## Adult Dosing
The typical adult regimen is:
* Lansoprazole 30 mg, Amoxicillin 1 gram, and Clarithromycin 500 mg, all taken orally twice daily for 14 days.
* Alternatively, a 10-day regimen may be used, with dosing twice daily: Lansoprazole 30 mg, Amoxicillin 1 gram, and Clarithromycin 500 mg.
**Note:** Dosing frequency and duration may vary based on local resistance patterns and prescribing guidelines.
## Pediatric Dosing
* Data for the use of this specific combination product in pediatric patients is limited. Dosing for individual components in pediatric patients is available but extrapolation to the combination requires expert consultation. Lansoprazole pediatric dosing varies by age and weight. Amoxicillin and clarithromycin pediatric dosing is typically weight-based.
## Dose Adjustments
* **Renal Impairment:** Dose adjustment for lansoprazole is generally not required. For amoxicillin, consider reducing the dose or increasing the dosing interval in severe renal impairment. Clarithromycin dose should be reduced in severe renal impairment (CrCl < 30 mL/min). Due to the combination product, separate formulations may be necessary for dose adjustment.
* **Hepatic Impairment:** Dose adjustment for lansoprazole may be necessary. For clarithromycin, a 50% dose reduction is recommended in patients with hepatic impairment and normal renal function.
## Contraindications
* Hypersensitivity to lansoprazole, amoxicillin, clarithromycin, other macrolides, or penicillins.
* History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
* Concomitant use of lansoprazole with rilpivirine.
## Adverse Effects
Common adverse effects include diarrhea, headache, nausea, abdominal pain, taste perversion, rash, and oral thrush. Serious adverse effects can include severe allergic reactions, *Clostridioides difficile*-associated diarrhea, QT prolongation (with clarithromycin), and hepatic dysfunction.
## Key Drug Interactions
* **Lansoprazole:** May decrease the absorption of drugs that require acidic environments (e.g., ketoconazole, itraconazole, atazanavir). May increase levels of drugs metabolized by CYP3A4 (e.g., warfarin, phenytoin, diazepam). Concurrent use with rilpivirine is contraindicated.
* **Clarithromycin:** Potent inhibitor of CYP3A4. May increase serum concentrations of numerous drugs, including statins, some calcium channel blockers, benzodiazepines, and colchicine, potentially leading to toxicity. Avoid coadministration with cisapride, pimozide, and domperidone.
* **Amoxicillin:** May decrease the efficacy of oral contraceptives.
## Monitoring
* Monitor for signs and symptoms of allergic reactions.
* Assess for diarrhea and signs of *C. difficile* infection.
* Monitor liver function tests, especially with prolonged therapy or in patients with hepatic impairment.
* If co-administered with warfarin, monitor INR closely.
## Clinical Pearls
* Administer the combination product before a meal to maximize lansoprazole's efficacy.
* Ensure patient compliance with the full 10- or 14-day course to maximize eradication rates and minimize resistance development.
* Due to the potential for significant drug interactions, a thorough medication reconciliation is crucial before initiating therapy.
* Consider local *H. pylori* resistance patterns when selecting antibiotic regimens.
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for definitive patient management decisions.
